| name | endo-paget-bisphosphonate-pre-joint-replacement |
| description | This skill suggests administering a bisphosphonate before elective total joint replacement to reduce intraoperative hemorrhaging and postoperative loosening of the prosthesis in patients with severe osteoarthritis adjacent to Paget's disease bone. Trigger phrases include preoperative planning for joint replacement in a patient with Paget's disease affecting the adjacent bone. |
Administer bisphosphonate before total joint replacement in severe osteoarthritis
STEP 1 — Gather Information
Confirm Paget's disease involving bone adjacent to the joint slated for replacement (plain radiographs or radionuclide bone scan). Assess osteoarthritis severity (clinical/radiographic). Screen for bisphosphonate contraindications: renal function (eGFR), serum calcium, vitamin D level, and signs of hypocalcemia. Obtain baseline alkaline phosphatase or bone turnover marker if available.
STEP 2 — Rule In / Rule Out
Is there severe osteoarthritis of a joint adjacent to radiographically confirmed Paget's disease bone? If YES, proceed to step 3. If NO, follow standard joint replacement pathway without prophylactic bisphosphonate.
STEP 3 — Classify or Stratify
Assess renal function: if eGFR ≥35 mL/min and no hypocalcemia, classify as eligible for IV zoledronate. If eGFR <35 or uncorrected hypocalcemia/vitamin D deficiency, classify as ineligible for IV zoledronate; consider oral bisphosphonate alternative or delay treatment after correction.
STEP 4 — Decide
Administer a single 5 mg intravenous zoledronate infusion over at least 15 minutes, schedule elective total joint replacement 1–2 months later, and ensure calcium and vitamin D repletion peri‑operatively. Monitor for acute‑phase reaction (fever, myalgia) and treat symptomatically with acetaminophen or NSAIDs if not contraindicated.
Clinical Guardrails / Mimics / Pitfalls
Do not give zoledronate in severe renal impairment (eGFR <35) without dose adjustment; avoid in uncorrected hypocalcemia or vitamin D deficiency. Do not rely on analgesics alone to mitigate surgical risk. Avoid NSAIDs if they worsen renal function or GI bleeding risk. Do not administer if pregnancy is possible. Remember that bisphosphonate effect on bone turnover takes weeks; surgery too soon (<1 month) may not reduce bleeding risk.
Concrete Clinical Example
A 68‑year‑old man with Paget’s disease of the right femur and severe hip osteoarthritis is listed for total hip replacement. Pre‑op work‑up shows eGFR 58 mL/min, normal calcium, vitamin D 32 ng/mL. He receives zoledronate 5 mg IV today; surgery is scheduled for 6 weeks later. He takes calcium and vitamin D daily and reports only mild myalgia after infusion, managed with acetaminophen.
Source: Endocrine Society Clinical Practice Guideline: Paget’s Disease of Bone, 2014, DOI:10.1210/jc.2014-2910
